A Phase 1 interventional study of CHF10067 starting dose -- 1000mg (Cohort A) and CHF10067 intermediate dose -- 2000mg (Cohort B) in Idiopathic Pulmonary Fibrosis, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 9 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 21 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.
Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 52nd largest by enrollment of the 83 interventional ones that give a count, is one of 8 that started in 2023, is one of 15 in phase 1, and was the 73rd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom, United States, North Macedonia and 1 more country
Ages 40+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 40+
Avalyn Pharma Inc. · Sites in United Kingdom, Australia, Canada and 4 more countries
Ages 40+
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18–85 · Healthy volunteers
Rein Therapeutics · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 40+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 46 · Phase 3 15 · Phase 4 3
First in 2000; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is close to the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 109 across the 83 interventional studies, 132 across the 20 observational. Of the 74 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 103 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
Chiesi Farmaceutici S.p.A. has 3 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT07194382Avalyn Pharma Inc.AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | 2026-12 |
| NCT06588686Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | 2027-05 |
| NCT06488638University Hospital Southampton NHS Foundation TrustPilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 2027-06-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assess the safety of CHF10067 (study drug) and any side effects that might be associated with it. The study also evaluated how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug was evaluated.
Chiesi conducted this study in patients affected by idiopathic pulmonary fibrosis (IPF, a progressive and chronic lung disease). Chiesi performed this study to establish the drug doses that would be suitable for future studies (a dose finding study).
The principal aim of this study was to obtain safety and tolerability data when CHF10067 was administered intravenously as single ascending doses to subjects with IPF (a progressive and chronic lung disease). This information, together with the pharmacokinetic (PK) and immunogenicity data is part of a dose finding efforts, for future clinical studies. The effect of CHF10067 on transglutaminase 2 (TG2) levels was also investigated as an exploratory endpoint.
A sequential group, single ascending dose design has been chosen for safety reasons because CHF10067 is in the early stages of clinical development and no data in the IPF population has been collected so far. In addition, sentinel dosing was used so that in each cohort 2 subjects (1 CHF10067 and 1 placebo) was administered at least 24 hours, before the remaining 6 subjects.
The study was double-blind and placebo-controlled to avoid bias in the collection and evaluation of data during its conduct. Placebo was chosen as the comparison treatment to assess whether any observed effects are treatment-related or reflect the study conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single intravenous (IV) dose of CHF10067
Biological: CHF10067 starting dose -- 1000mg (Cohort A) · Biological: CHF10067 intermediate dose -- 2000mg (Cohort B) · Biological: CHF10067 high dose -- 3000mg (Cohort C)
A single dose of placebo (commercial source of 0.9% sodium chloride aqueous solution)
Drug: Placebo
Intravenous administration of a starting dose of the monoclonal antibody
Intravenous administration of an intermediate dose of the monoclonal antibody
Intravenous administration of a high dose of the monoclonal antibody
Intravenous administration of a physiological solution as placebo
1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEs
Evaluate reported adverse events (AEs) and serious adverse events (SAEs). The number of subjects affected by AEs or SAEs is presented below. Please note: comprehensive summaries of AEs and SAEs are presented in section 'Adverse Events'; these include the preferred term of the AE or SAE, the number of subjects affected, and the number of events for a each preferred term.
Time frame: From pre-dose (baseline) up to day 84.
2_Systemic Exposure [Area Under the Concentration-time Curve From Zero to Time (AUC0-t)]
Evaluate the area under the concentration-time curve (AUC) from zero to the last quantifiable concentration (AUC0-t) of CHF10067 after a single dose.
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
3_Area Under the Concentration-time Curve (AUC) From Zero to Infinity (AUC0-∞)
Evaluate the area under the concentration-time curve (AUC) from zero to infinity (AUC0-∞) of CHF10067 after a single dose.
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
4_Pharmacokinetics -- Maximum Plasma Concentration (Cmax)
Evaluate the Cmax (maximum observed concentration) after a single dose of CHF10067.
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
5_Pharmacokinetics -- Time to Maximum Observed Concentration (Tmax)
Evaluate the time to maximum observed concentration (tmax).
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
6_Pharmacokinetics -- Serum Concentration at the End of Infusion (Cinf)
Evaluate serum concentration at the end of infusion (Cinf) of CHF10067.
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion (up to 6 hours from the start of infusion).
7_Pharmacokinetics -- Time at the End of Infusion (Tinf)
Evaluate the time of serum concentration at the end of infusion (Tinf). Time at the end of the infusion.
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion (up to 6 hours from the start of infusion).
8_Pharmacokinetics -- Clearance (CL)
Evaluate clearance (CL) of CHF10067.
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
9_Pharmacokinetics -- Volume of Distribution (Vz)
Evaluate volume of distribution (Vz) CHF10067.
Time frame: Pre-dose (within 75 min from start of infusion, baseline), at the end of infusion, 2, 4, 8, and 20 h after the end of infusion and 5, 7, 14, 28, 56, and 84 days post-dose.
10_Pharmacokinetics -- Terminal Half-life (t1/2)
Evaluate the terminal half-life (t1/2) of CHF10067.
Time frame: From pre-dose (baseline) up to day 84.
11_Spirometry -- Forced Expiratory Volume in the First Second (FEV1) -- Percent Predicted -- Change From Baseline
Forced expiratory volume in the first second (FEV1) parameters, summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.
Time frame: Pre-dose (baseline), and on 7, 28, 56, and 84 day post-dose.
12_Spirometry -- Forced Vital Capacity (FVC) -- Percent Predicted -- Change From Baseline
Forced vital capacity (FVC) parameters will be summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.
Time frame: Text adjusted Pre-dose (baseline), and on 7, 28, 56, and 84 day post-dose.
13_Vital Signs -- Abnormal Changes in Systolic and Diastolic Blood Pressure
Evaluate abnormal changes in systolic and diastolic blood pressure from baseline at any post-baseline time point.
Time frame: From pre-dose (baseline) up to day 84.
14_Immunogenicity Profile -- Anti-drug Antibody (ADA) and Neutralising Antibody (nAb).
Evaluate the immunogenicity profile of CHF 10067 in serum, with respect to the development of anti-drug antibody (ADA) and neutralising antibody (nAb). A robust immunogenicity profile indicates the potential for the drug to trigger an immune response in patients, leading to the formation of ADAs. These antibodies can affect the drug's efficacy, safety, and pharmacokinetics. Detecting the presence of ADAs in serum samples was performed using an enzyme linked immunosorbent assay (ELISA), a validated assay method. Neutralizing Antibody (nAb) are a subset of ADAs that can interfere with the drug's therapeutic activity by blocking its binding to the target or inhibiting its downstream effects. The presence of ADAs and nAbs can affect the drug's pharmacokinetics (PK) by altering its absorption, distribution, metabolism, and excretion. This can lead to changes in drug exposure and potentially impact efficacy and safety.
Time frame: Pre-dose (baseline), at day 14, 28, 56, 84, and in case of early termination.
For the study, 52 male and female subjects were screened 3-28 days before randomization; of these, 27 subjects were screening failures. Overall, 25 subjects were randomized; of these 1 subject (CHF 10067 3000 mg) did not receive the study medication due to technical reasons.
| Milestone | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Not treated due to technical reasons | 0 | 0 | 1 | 0 |
Evaluate reported adverse events (AEs) and serious adverse events (SAEs). The number of subjects affected by AEs or SAEs is presented below. Please note: comprehensive summaries of AEs and SAEs are presented in section 'Adverse Events'; these include the preferred term of the AE or SAE, the number of subjects affected, and the number of events for a each preferred term.
| Participants | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| Serious TEAE | 0 | 0 | 1 | 0 |
| Non-serious TEAE | 4 | 3 | 5 | 4 |
| AE leading to study treatment discontinuation | 0 | 0 | 0 | 0 |
| AE leading to death | 0 | 0 | 0 | 0 |
Evaluate the area under the concentration-time curve (AUC) from zero to the last quantifiable concentration (AUC0-t) of CHF10067 after a single dose.
| day.μg/mL | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 2_Systemic Exposure [Area Under the Concentration-time Curve From Zero to Time (AUC0-t)] | 3424 ± 647 | 7902 ± 1001 | 15592 ± 3027 |
Evaluate the area under the concentration-time curve (AUC) from zero to infinity (AUC0-∞) of CHF10067 after a single dose.
| day.μg/mL | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 3_Area Under the Concentration-time Curve (AUC) From Zero to Infinity (AUC0-∞) | 3450 ± 660 | 8141 ± 1112 | 16328 ± 3245 |
Evaluate the Cmax (maximum observed concentration) after a single dose of CHF10067.
| μg/mL | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 4_Pharmacokinetics -- Maximum Plasma Concentration (Cmax) | 307 ± 43.9 | 668 ± 126 | 1067 ± 173 |
Evaluate the time to maximum observed concentration (tmax).
| hour | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 5_Pharmacokinetics -- Time to Maximum Observed Concentration (Tmax) | 1.69 (1.67 to 3.67) | 3.78 (3.58 to 11.67) | 5.39 (5.35 to 7.43) |
Evaluate serum concentration at the end of infusion (Cinf) of CHF10067.
| μg/mL | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 6_Pharmacokinetics -- Serum Concentration at the End of Infusion (Cinf) | 304 ± 44.6 | 658 ± 138 | 1065 ± 174 |
Evaluate the time of serum concentration at the end of infusion (Tinf). Time at the end of the infusion.
| hour | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 7_Pharmacokinetics -- Time at the End of Infusion (Tinf) | 1.68 (1.67 to 1.72) | 3.69 (3.58 to 3.85) | 5.38 (5.35 to 5.50) |
Evaluate clearance (CL) of CHF10067.
| liter/day | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 8_Pharmacokinetics -- Clearance (CL) | 0.295 ± 0.0489 | 0.250 ± 0.0357 | 0.190 ± 0.0363 |
Evaluate volume of distribution (Vz) CHF10067.
| liter | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 9_Pharmacokinetics -- Volume of Distribution (Vz) | 4.93 ± 0.969 | 5.99 ± 0.716 | 5.21 ± 1.03 |
Evaluate the terminal half-life (t1/2) of CHF10067.
| days | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) |
|---|---|---|---|
| 10_Pharmacokinetics -- Terminal Half-life (t1/2) | 11.7 ± 2.20 | 16.8 ± 2.32 | 19.1 ± 1.93 |
Forced expiratory volume in the first second (FEV1) parameters, summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.
| percent predicted FEV1 | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| Day 7 | 3.93 ± 3.35 | 0.50 ± 2.74 | -0.20 ± 1.34 | -0.43 ± 2.60 |
| Day 28 | 3.76 ± 3.66 | -0.55 ± 3.06 | -2.93 ± 2.81 | -0.55 ± 3.37 |
| Day 56 | 3.18 ± 3.58 | -0.68 ± 3.54 | -0.75 ± 5.68 | -1.35 ± 2.93 |
| Day 84 | 0.13 ± 5.57 | 0.36 ± 4.30 | -2.70 ± 2.93 | -1.40 ± 3.62 |
Forced vital capacity (FVC) parameters will be summarised using descriptive statistics at each analysis time point by treatment. Summary results show the change from baseline of the percent predicted.
| percent predicted FVC | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| Day 7 | 3.12 ± 2.24 | -0.90 ± 3.31 | -0.50 ± 2.89 | -0.92 ± 3.80 |
| Day 28 | 2.70 ± 3.74 | -0.50 ± 2.58 | -3.23 ± 2.76 | -0.13 ± 4.10 |
| Day 56 | 2.50 ± 1.87 | -1.17 ± 3.12 | -1.42 ± 6.55 | -0.90 ± 2.84 |
| Day 84 | -0.72 ± 4.02 | -0.36 ± 3.56 | -1.98 ± 3.79 | -1.97 ± 3.22 |
Evaluate abnormal changes in systolic and diastolic blood pressure from baseline at any post-baseline time point.
| Participants | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| Systolic Blood Pressure Decrease From Baseline >20 mmHg | 3 | 0 | 1 | 2 |
| Systolic Blood Pressure Increase From Baseline >20 mmHg | 1 | 0 | 1 | 2 |
| Diastolic Blood Pressure Decrease From Baseline >10 mmHg | 3 | 5 | 5 | 4 |
| Diastolic Blood Pressure Increase From Baseline >10 mmHg | 2 | 2 | 2 | 3 |
Evaluate the immunogenicity profile of CHF 10067 in serum, with respect to the development of anti-drug antibody (ADA) and neutralising antibody (nAb). A robust immunogenicity profile indicates the potential for the drug to trigger an immune response in patients, leading to the formation of ADAs. These antibodies can affect the drug's efficacy, safety, and pharmacokinetics. Detecting the presence of ADAs in serum samples was performed using an enzyme linked immunosorbent assay (ELISA), a validated assay method. Neutralizing Antibody (nAb) are a subset of ADAs that can interfere with the drug's therapeutic activity by blocking its binding to the target or inhibiting its downstream effects. The presence of ADAs and nAbs can affect the drug's pharmacokinetics (PK) by altering its absorption, distribution, metabolism, and excretion. This can lead to changes in drug exposure and potentially impact efficacy and safety.
| Participants | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| 1_Baseline ADA positive | 0 | 0 | 0 | 0 |
| 2_ADA prevalence | 1 | 0 | 0 | 0 |
| 3_ADA incidence (ADA+) | 1 | 0 | 0 | 0 |
| 4_Duration of ADA Persistently positive ADA | 0 | 0 | 0 | 0 |
| 5_Duration of ADA Transiently positive ADA | 1 | 0 | 0 | 0 |
| 6_Treatment-boosted ADA | 0 | 0 | 0 | 0 |
| 7_nAb positive at any visit | 1 | 0 | 0 | 0 |
Collected over Adverse events (AE) were reported from the time of patient informed consent signature until subject's study participation ended (day 84 or early withdrawal).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CHF 10067 1000 mg (Test Treatment) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| CHF 10067 2000 mg (Test Treatment) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| CHF 10067 3000 mg (Test Treatment) | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| InfluenzaInfections and infestations | 0/6 | 0/6 | 1/6 | 0/6 |
| Event | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo |
|---|---|---|---|---|
| Lower Respiratory Tract InfectionInfections and infestations | 2/6 | 0/6 | 0/6 | 0/6 |
| NasopharyngitisInfections and infestations | 0/6 | 2/6 | 0/6 | 1/6 |
| DizzinessNervous system disorders | 2/6 | 0/6 | 0/6 | 0/6 |
| HeadacheNervous system disorders | 0/6 | 0/6 | 2/6 | 1/6 |
| HypertensionVascular disorders | 1/6 | 0/6 | 2/6 | 0/6 |
| Supraventricular ExtrasystolesCardiac disorders | 0/6 | 0/6 | 0/6 | 1/6 |
| Periorbital OedemaEye disorders | 1/6 | 0/6 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 1/6 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 1/6 |
| Age, Continuous(years) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 60.7 ± 7.3 | 61.8 ± 8.0 | 58.7 ± 8.2 | 70.7 ± 4.1 | 63.0 ± 8.1 |
| Sex: Female, Male(Participants) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| Female | 1 | 2 | 5 | 0 | 8 |
| Male | 5 | 4 | 1 | 6 | 16 |
| Race (NIH/OMB)(Participants) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 6 | 6 | 6 | 24 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 25.98 ± 2.17 | 30.23 ± 3.66 | 30.02 ± 4.18 | 27.80 ± 1.90 | 28.51 ± 3.42 |
| Smoking status at screening(Participants) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| Tobacco: Ex-smoker | 3 | 3 | 3 | 4 | 13 |
| Tobacco: Non-smoker | 3 | 3 | 3 | 2 | 11 |
| E-cigarettes: Ex-smoker | 0 | 0 | 0 | 0 | 0 |
| E-cigarettes: Non-smoker | 6 | 6 | 6 | 6 | 24 |
| Duration of smoking(years) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 40.3 ± 7.8 | 33.7 ± 16.3 | 21.7 ± 5.7 | 24.5 ± 16.3 | 29.6 ± 13.5 |
| Number of pack-years(pack-years) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 18.60 ± 8.79 | 22.43 ± 18.60 | 20.00 ± 7.00 | 18.00 ± 13.98 | 19.62 ± 11.43 |
| Time since diagnosis(years) | CHF 10067 1000 mg (Test Treatment) | CHF 10067 2000 mg (Test Treatment) | CHF 10067 3000 mg (Test Treatment) | Placebo | Total |
|---|---|---|---|---|---|
| Median | 1.25 (0.6 to 4.1) | 0.79 (0.3 to 4.1) | 1.21 (0.0 to 4.4) | 1.40 (0.2 to 4.6) | 1.00 (0.0 to 4.6) |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2023 to primary completion in Jun 2024, 16 months.
Results were first posted in Aug 2025, 1 year 1 month after primary completion.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →